Mustang Bio - MBIO STOCK NEWS

Mustang Bio (NASDAQ: MBIO) announced that Dr. Mazyar Shadman will present interim data on MB-106, a CD20-targeted CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, at two key conferences. The presentations will occur at the 2022 Tandem Meetings (April 23-26) and iwCAR-T (April 28-May 1). Initial findings indicate promising clinical efficacy and safety of MB-106, which is in a Phase 1/2 trial at Fred Hutch. The company plans to start a multicenter trial under its IND soon. The autologous CAR-T therapy was collaboratively developed with Fred Hutch.

Mustang Bio (NASDAQ: MBIO) announced positive interim results from ongoing Phase 1 clinical trials of MB-101 (a CAR T cell therapy) and MB-108 (an oncolytic virus) for recurrent glioblastoma (rGBM). Research presented by Dr. Christine Brown at the AACR Annual Meeting 2022 indicates these therapies are well tolerated, with preliminary safety data supporting the development of a combination therapy, MB-109, which aims to enhance treatment efficacy. Mustang plans to file an Investigational New Drug application for MB-109 later this year, aiming to address the challenges of rGBM treatment.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, announced its participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. Mustang’s management will present a corporate overview and join a panel discussion on April 6 at 1:30 p.m. ET. Interested parties can register for the event here. A webcast will be available for 30 days post-event on the Investor Relations section of Mustang’s website.

Mustang Bio, Inc. (NASDAQ: MBIO) reported its financial results and corporate highlights for 2021, achieving significant advancements in cell and gene therapies. The FDA approved two IND applications for pivotal trials of MB-107 and MB-106, targeting severe combined immunodeficiency and non-Hodgkin lymphoma, respectively. The company raised $2 million from the National Cancer Institute to support its trials. Despite a net loss of $66.4 million, liquidity improved to $110.6 million. With several upcoming clinical trials and promising interim data, Mustang aims for further growth in 2022.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in March 2022. CEO Manuel Litchman will engage in a fireside chat at Oppenheimer’s Virtual Healthcare Conference on March 15 at 4:00 p.m. ET. Additionally, Mustang will present on-demand at H.C. Wainwright’s Gene Therapy Conference starting March 30 and participate in a panel at Cantor Fitzgerald’s Rare Disease Summit the same day. These events highlight Mustang's commitment to advancing cell and gene therapies for various diseases.

Mustang Bio (NASDAQ: MBIO) announced that an abstract regarding Phase 1 trials of its oncolytic viral and CAR T-cell therapies for glioblastoma (GBM) has been selected for a late-breaking poster presentation at the AACR Annual Meeting 2022, scheduled for April 8-13 in New Orleans. City of Hope’s Dr. Christine Brown will present the data, highlighting the combination of MB-108 oncolytic virus and MB-101 CAR T-cell therapy, together referred to as MB-109. An Investigational New Drug application for MB-109 is anticipated later this year.

Mustang Bio (NASDAQ: MBIO) announced the completion of a $75 million long-term debt facility with Runway Growth Capital. The initial $30 million was funded upon closing, with the remaining $45 million contingent on achieving predetermined milestones. This financing is expected to enhance Mustang's financial flexibility and support multiple clinical trials in 2022. The loan will be repaid through a combination of interest-only payments followed by principal repayments over 60 months. Mustang aims to advance its cell and gene therapies targeting hematologic cancers and rare genetic diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced that clinical trial data for its PSCA CAR T-cell therapy, MB-105, has been selected for presentation at the 2022 ASCO Genitourinary Cancers Symposium. The Phase 1 trial aims to assess dose limiting toxicity and preliminary efficacy in patients with PSCA-positive mCRPC. So far, 12 patients have been treated, and results indicate the therapy is feasible with a potential anti-tumor effect. Notably, no dose limiting toxicities were observed at the 100M cell dose, while some grade 3 non-infective cystitis occurred at higher doses.

Mustang Bio (NASDAQ: MBIO) has been awarded the Bronze winner for the Central region in the Eighteenth Annual Team Massachusetts Economic Impact Awards, recognizing its significant contributions to the local economy. The company achieved job growth by adding 56 new positions since January 2020 and maintains a diverse workforce with 53% women and 26% minority employees. Mustang invested $2.5 million in a 6,000 square-foot facility expansion aimed at scaling its manufacturing of cell and gene therapies. The award ceremony is scheduled for April 7, 2022.